Literature DB >> 8639928

Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation.

J E Sanders1, J Hawley, W Levy, T Gooley, C D Buckner, H J Deeg, K Doney, R Storb, K Sullivan, R Witherspoon, F R Appelbaum.   

Abstract

Patients successfully treated with a marrow transplant often have concerns about fertility and pregnancy. This study was performed to determine pregnancy outcome among patients who had received high-dose chemotherapy alone or with total-body irradiation (TBI) and marrow transplantation for aplastic anemia or hematologic malignancy. Records of 1,326 postpubertal and 196 prepubertal patients currently more than 12 years of age after marrow transplant in Seattle from August 1971 to January 1992 were reviewed to determine the patients with normal gonadal function and pregnancies. Among 708 postpubertal women, 110 recovered normal ovarian function and 32 became pregnant. In addition, nine formerly prepubertal girls with normal gonadal function became pregnant. Among 618 postpubertal men, 157 recovered testicular function and partners of 33 became pregnant. An additional two formerly prepubertal men had partners who became pregnant. Forty-one female patients and partners of 35 male patients had 146 pregnancies after transplant. All 76 patients responded to a questionnaire requesting pregnancy history, outcome, infant birth weight, and congenital anomalies information for all clinically recognized pregnancies. There were 115 live births among 146 (79%) pregnancies. Spontaneous abortion terminated four of 56 (7%) pregnancies for 28 female cyclophosphamide (CY) recipients and six of 16 (37%) pregnancies for 13 TBI recipients (P = .02). Partners of 28 male CY recipients had four of 62 (6.4%) pregnancies terminate with spontaneous abortion, but there were no spontaneous abortions among eight pregnancies of five TBI recipients' partners. Preterm delivery occurred for eight of 44 (18%) and five of eight (63%) live births for 24 CY and eight TBI female recipients (P = .01). This 25% incidence among all female patient pregnancies is higher than the expected incidence of 8% to 10% (P = .0001). The 13 preterm deliveries resulted in 10 low birth weight ([LBW] 1.8 to 2.24 kg) and three very low birth weight ([VLBW] < or = 1.36 kg) infants, for an overall incidence of 25%, which is higher than the expected incidence of 6.5% for the general population (P = .0001). Twelve of the 13 premature infants survive. Congenital anomalies were seen among two of 52 (3.8%) live-born infants of female and six of 63 (9.5%) live-born infants of male patients, which is not different from the 13% of single congenital anomalies reported for the general population. These data demonstrate that clinically recognized pregnancies among women who have received a marrow transplant incorporating TBI are likely to be accompanied by an increased risk of spontaneous abortion. Pregnancies among all women who received a marrow transplant are likely to be accompanied by preterm labor and delivery of LBW or VLBW babies who do not seem to be at an increased risk of congenital anomalies. However, determination of possible adverse effects of parental exposure to high-dose alkylating agents with or without TBI on children born posttransplant requires longer, additional follow-up.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639928

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  115 in total

Review 1.  Fertility preservation for children treated for cancer (1): scientific advances and research dilemmas.

Authors:  R Grundy; R G Gosden; M Hewitt; V Larcher; A Leiper; H A Spoudeas; D Walker; W H Wallace
Journal:  Arch Dis Child       Date:  2001-04       Impact factor: 3.791

Review 2.  Hematopoietic stem cell transplantation for severe combined immune deficiency.

Authors:  K I Weinberg; N Kapoor; A J Shah; G M Crooks; D B Kohn; R Parkman
Journal:  Curr Allergy Asthma Rep       Date:  2001-09       Impact factor: 4.806

Review 3.  Developing strategies for long term follow up of survivors of childhood cancer.

Authors:  W H Wallace; A Blacklay; C Eiser; H Davies; M Hawkins; G A Levitt; M E Jenney
Journal:  BMJ       Date:  2001-08-04

4.  Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study.

Authors:  Lisa B Signorello; John J Mulvihill; Daniel M Green; Heather M Munro; Marilyn Stovall; Rita E Weathers; Ann C Mertens; John A Whitton; Leslie L Robison; John D Boice
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

Review 5.  Hematopoietic stem cell transplantation: a primer for the primary care physician.

Authors:  Chantal S Léger; Thomas J Nevill
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

6.  Changes in plasma müllerian-inhibiting substance and brain-derived neurotrophic factor after chemotherapy in premenopausal women.

Authors:  Muhammad Faisal Aslam; Zaher O Merhi; Safaa Ahmed; Oumar Kuzbari; David B Seifer; Howard Minkoff
Journal:  Fertil Steril       Date:  2011-04       Impact factor: 7.329

7.  Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients.

Authors:  Yee Chung Cheng; Mariko Takagi; Andrea Milbourne; Richard E Champlin; Naoto T Ueno
Journal:  Oncologist       Date:  2012-01-26

8.  NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.

Authors:  Christopher C Dvorak; Clarisa R Gracia; Jean E Sanders; Edward Y Cheng; K Scott Baker; Michael A Pulsipher; Anna Petryk
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

Review 9.  Fertility preservation and management of gonadal failure associated with lymphoma therapy.

Authors:  Simon J Howell; Stephen M Shalet
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

Review 10.  Fertility Management for the Hemato-Oncologist.

Authors:  Parathan Karunakaran; Pankaj Malhotra; Deepesh Lad
Journal:  Indian J Hematol Blood Transfus       Date:  2017-10-11       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.